New Publication: Bulletin MADRAC - April 2016

Print

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Bulletin MADRAC

April 2016

 

  • Welcoming the new MADRAC members (2016-2018)
  • Pharmacogenomics in Determining Drug Response
  • Azithromycin: Risk of QT Prolongation and DRESS
  • Mycophenolate: Important New Information on the Teratogenic Risk
  • Prolia® and Xgeva® (denosumab): Clinically Significant Cases of Hypercalcaemia after Cessation of Treatment with Denosumab in Paediatric Patients
  • Viekirax® and Exviera®: Not Recommended in Patients with Moderate Hepatic Impairment (Child-Pugh B)
  • Xalkori® (crizotinib): Inclusion of a New Warning Regarding Cardiac Failure
  • Pharmacists: CPD Points for Quality ADR Reports

 



 
 
  DOWNLOAD PDF